Therefore, the study aimed to evaluate the predictive value of pHER2Y1248 coexpressed with other ErbB family members and hormone receptors in HER2-overexpressing BC patients postoperatively treated with trastuzumab-based therapy. This evidence concerns the gene ERBB2 and breast cancer.